Tumor type | IL-15 isotype employed | Outcome | Reference |
B-16 melanoma | rhIL-15+adoptive cell transfer | Tumor regression | 65 |
Metastatic colon carcinoma | Murine recombinant IL-15 (mrIL-15)+blockade of checkpoints inhibition | Longer survival of tumor-bearing animals | 66 |
Colon carcinoma | mrIL-15+anti-CD40 Abs | Longer survival of tumor-bearing mice | 67 |
Lung cancer | DC transduced with viral vectors based on simian virus 40 expressing IL-15 (rSVIL-15) | Complete tumor remission in 73% of mice | 68 |
MC38 colon carcinoma and TC-1 epithelial carcinoma | Superagonist het IL-15 | delayed primary tumor growth+Increased NK and CD8+T cell tumor infiltration | 74 |
Colon carcinoma | Hyperagonist RLI+PD1 blockade | Complete tumor remission in 100% mice | 73 |
B-16 melanoma | Superagonist het IL-15+adoptive T cell transfer | Decreased of tumor size | 69 |
B-16 melanoma | Hyperagonist RLI | Reduced no | 70 |
B-16 melanoma | CD11c-driven IL-15 | Total lung metastasis inhibition | 80 |
4T1 mouse mammary carcinoma | Hyperagonist RLI | Lung metastasis inhibition | 72 |
Hyperagonist RLI, IL15Rα-linker-IL15. Is a fusion protein linking the NH2-terminal domains of IL15Rα to IL15 through a 20-amino acid linker
DC, dendritic cell; IL-15, interleukin 15; mrIL-15, murine recombinant IL-15; NK, natural killer; rhIL-15, human recombinant IL-15 ; rSVIL-15, simian virus 40 expressing IL-15.